Chinook Therapeutics has entered a collaboration agreement with Ionis Pharmaceuticals, for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chronic kidney disease with significant unmet medical need.
The companies will leverage Chinook’s precision medicine approach and deep expertise in nephrology and Ionis’ extensive expertise in RNA-targeted therapeutics.
“We are pleased to collaborate with Ionis on this preclinical discovery program as we continue to strengthen Chinook’s position as the leading kidney disease company,” said Andrew King, D.V.M, Ph.D., chief scientific officer of Chinook.
“Developing an ASO therapy enhances our ability to target key genetic and molecular drivers and expands our precision medicine pipeline for rare severe chronic kidney diseases while continuing to pursue our goal of making dialysis and transplant unnecessary for people living with kidney disease.”
Under the terms of the agreement, Chinook will pay Ionis an undisclosed upfront payment as well as potential development and regulatory milestone payments and royalties. Ionis will be responsible for IND-enabling toxicology studies and Chinook will be responsible for clinical development and commercialization.